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Abstract A sensitive and speciﬁc liquid chromatography
electrospray ionisation–tandem mass spectrometry method
for determination of new non-imidazole histamine
H3 receptor antagonist 1-[3-(4-tert-butylphenoxy)pro-
pyl]piperidine (DL76) in rat serum has been developed and
validated. Chromatography was performed on a XBrid-
ge
TM C18 analytical column (2.1 9 30 mm, 3.5 lm,
Waters, Ireland) with gradient elution using a mobile phase
containing acetonitrile and water with an addition of 0.1%
of formic acid. Detection was achieved by an Applied
Biosystems MDS Sciex (Concord, Ontario, Canada) API
2000 triple quadrupole mass spectrometer. Electrospray
ionization (ESI) was used for ion production. The limit of
detection in the SRM mode was found to be 0.5 ng mL
-1.
The limit of quantiﬁcation was 1 ng mL
-1. The precision
and accuracy for both intra- and inter-day determination of
DL76 ranged from 1.65 to 15.09% and from 88.74 to
113.43%. The results of this analytical method validation
allow to carry out pharmacokinetic studies in rats. The
method was used for the pilot study of the pharmacokinetic
behavior of DL76 in rats after intravenous administration.
Keywords Column liquid chromatography  Tandem MS
detection  DL76 compound  Histamine H3 receptor
antagonist  Rats serum
Introduction
Thebiogenicaminehistamineisimplicatedinthewiderange
of physiological and pathophysiological functions. It is a
ligandforfourhistaminergicreceptorssubtypes,fromwhich
receptorH3isactingaspresynaptic auto-andheteroreceptor
mainly in the CNS controlling the synthesis and release of
histamine. Its activation modulates also the release of vari-
ous important neurotransmitters, such as dopamine, acetyl-
choline, norepinephrine, serotonin, GABA, glutamate and
substance P. Therefore, histaminic neurons and the cross-
linkage between major neurotransmitter systems are
involved in many brain functions including vigilance,
memoryprocesses,feedingbehaviorandlocomotoractivity.
Blockade of the H3 autoreceptors by antagonists inter-
rupts the negative feedback mechanism and leads to
increased levels of histamine and other neurotransmitters.
These effects suggest its potential therapeutic role for the
treatment of several diseases and neurological disorders,
such as schizophrenia, depression, sleep-wake disorders,
dementia or epilepsy.
Known compounds, H3 receptor antagonists, which are
imidazole derivatives make poor candidates for drugs due
to their tendency to inhibit numerous mammalian Cyt 450
isozymes and in case of a CNS drugs, their low brain
penetration. Therefore, a signiﬁcant effort was undertaken
to identify non-imidazole-derived H3 antagonists [1–4].
The example of such compound is DL76 (1-[3-(4-tert-
butylphenoxy)propyl]piperidine) which in preliminary
pharmacological studies showed good afﬁnity for human
H3 receptor stably expressed in CHO-K1 cells (hKi equal
22±3 nM) [5].
Preliminarily, both pharmacodynamic as well as phar-
macokinetic characteristics of any new compound, poten-
tial drug, require availability of a validated analytical
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DOI 10.1007/s10337-011-1983-9method, therefore, the purpose of this study was to develop
and validate a high performance liquid chromatography–
tandem mass spectrometry method (LC–MS–MS) for
quantiﬁcation of DL76 compound in rat serum samples.
The new method was successfully applied to a pilot study
of pharmacokinetics of DL76 in rats.
Experimental
Chemicals and Materials
The 1-[3-(4-tert-butylphenoxy)propyl]piperidine was sup-
plied from the Department of Technology and Biotechnol-
ogy of Drugs (Faculty of Pharmacy, Jagiellonian University
Medical College, Krakow, Poland). Pentoxifylline (3,7-
dimethyl-1-(5-oxohexyl)-3,7-dihydro-1H-purine-2,6-dione,
PTX), used as an internal standard, was obtained from
Sigma (St. Louis, MO, USA). HPLC grade acetonitrile,
water, formic acid and ethyl acetate were purchased from
Merck (Darmstadt, Germany). Control serum was obtained
from adult male Wistar rats Krf:(WI)WV (Charles River
Laboratory, Germany). Rats were injected intraperitoneally
with thiopental (70 mg kg
-1), and blood was collected after
decapitation. The serum samples were separated by cen-
trifugation (3,000 rpm, 10 min) and stored at -30 C until
used.
Instrumentation and Operating Conditions
Liquid Chromatographic Conditions
Liquid chromatography was performed using an Agilent
1100 HPLC (Agilent Technologies, Waldbronn, Germany)
system consisting of a degasser, a binary pump, a column
oven and an autosampler. Chromatographic separation was
carried out on XBridge
TM C18 analytical column
(2.1 9 30 mm, 3.5 lm, Waters, Dublin, Ireland) with the
oven temperature set at 30 C. The autosampler tempera-
ture was maintained at 10 C. The mobile phase of ace-
tonitrile (A) and water (B) with an addition of 0.1% of
formic acid was set at a ﬂow rate of 0.3 mL min
-1. Initial
mobile phase composition was 100% B with a linear gra-
dient to 30% B in the ﬁrst 8 min, then isocratic mode for
1 min with the following rapid change back to 100% B in
0.1 min. The remaining time of elution was set at 100% B.
The whole HPLC operation lasted 20 min. A sample vol-
ume of 10 lL was injected into LC–MS–MS system.
Mass Spectrometric Conditions
Mass spectrometric detection was performed on an Applied
Biosystems MDS Sciex (Concord, Ontario, Canada) API
2000 triple quadrupole mass spectrometer equipped with
an electrospray ionization (ESI) interface. ESI ionization
was performed in the positive ion mode. The tandem mass
spectrometer was operated at unit resolution in the selected
reaction monitoring mode (SRM), monitoring the transition
of the protonated molecular ions m/z 276 and 279 to the
product ions m/z 98 and 181 for DL76 and PTX,
respectively.
The mass spectrometric conditions were optimized for
DL76 by continuous infusion of the standard solution at the
rate of 10 lL min
-1 using a Harvard infusion pump. The
ion source temperature was maintained at 450 C. The
ionspray voltage was set at 5,500 V. The curtain gas (CUR)
was set at 10 and the collision gas (CAD) at 2. The optimal
collision energy (CE) was 50 V. The following parameters
of ion path were used as the most favorable ones: declus-
tering potential (DP) at 45 V, focusing potential (FP) at
300 V and entrance potential (EP) at 12 V. The quantiﬁ-
cation was performed via peak area ratio. Data acquisition
and processing were accomplished using the Applied
Biosystems Analyst version 1.4.2 software.
Preparation of Stock Solutions
The stock solutions of DL76 and PTX (IS) were prepared
at 1.0 mg mL
-1 in water. The stock solution of DL76 was
further serially diluted with water to make working solu-
tions at concentrations of 20, 10, 5, 2.5, 1, 0.5, 0.1 and
0.01 lgm L
-1. Internal standard working solution was
prepared by diluting the stock solution of PTX with water
to a concentration of 2.5 lgm L
-1. All stock and working
solutions were stored at 4 C.
Calibration Curve
Calibration curve was generated to conﬁrm the linear
relationship between the peak area ratio and the concen-
tration of DL76 in the test samples. Pooled blank serum
was spiked with an appropriate working solution to pro-
duce the calibration curve points equivalent to 2,000,
1,000, 500, 250, 100, 50, 10 and 1 ng mL
-1 of DL76
compound. Samples were made in ﬁve replicates and each
of them also contained a 10 lL of the IS working solution.
The results (peak area of analyte/peak area of IS) versus
concentration were ﬁtted to the linear equation. The quality
of ﬁt was evaluated by comparing back-calculated con-
centrations to the nominal ones.
Quality Control Samples
The quality control samples used during the validation and
in the pharmacokinetic studies have been prepared in the
same way as the calibration curve. Namely, they were
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123prepared by spiking blank serum with DL76 and IS and
produced at different concentrations along the calibration
range (LLOQ at 1 ng mL
-1, low at 40 ng mL
-1, medium
at 400 ng mL
-1 and high at 1,800 ng mL
-1 of DL76).
Extraction Procedures
Serum Samples
All analyzed samples were extracted employing a liquid–
liquid extraction technique into an ethyl acetate without
any modiﬁcation of pH. A 100 lL aliquot of rat serum was
pipetted out into a centrifuge tube and the working IS
solution (10 lL) was added. Then the samples were brieﬂy
mixed and 1 mL of ethyl acetate was added. The mixture
was shaken on a mechanical shaker for 20 min. After-
wards, samples were centrifuged at 3,000 rpm for 15 min
and the organic layer (0.5 mL) was transferred to the
conical tubes and evaporated to dryness at 37 C under the
gentle stream of nitrogen gas in the TurboVap evaporator
(Zymark, Hopkinton, MA, USA). The dry residue was
reconstituted with 100 lL of the acetonitrile/water (50/50,
v/v) mixture and an aliquot of 10 lL was injected onto the
LC–MS–MS system.
Method Validation
The analytical method was validated within the guidelines
established by the FDA for bioanalytical method validation.
Assay Speciﬁcity
The speciﬁcity of the method was evaluated by analyzing
blank serum samples from six rats. Each blank sample was
tested for any interference, also the ones associated with
thiopental, using the proposed extraction procedure and
chromatographic/mass spectrometric conditions and com-
pared with those obtained with an aqueous solution of the
analyte at a concentration near the lower limit of quanti-
ﬁcation (LLOQ). An assessment of absolute matrix effect
was done using matrix-free (solvent) samples and samples
containing extracted blank serum with an addition (post-
extraction) of an appropriate concentration of the DL76
compound. Three different concentration levels of DL76
were evaluated (40, 400, and 1,800 ng mL
-1) by analyzing
ﬁve samples at each level. For evaluation of the relative
matrix effect, ﬁve different sources of rat serum were used
[6, 7]. The relative ME was expressed as RSD (%).
The limit of detection (LOD) was estimated as a signal
to noise ratio (3:1). The lower limit of quantiﬁcation
(LLOQ) deﬁned in this assay was based on the expected
range for DL76 in the samples, as opposed to minimum
criteria of response or precision.
Precision and Accuracy
Precision of the assay was determined from the QC sam-
ples by replicate analysis of four concentration levels of
DL76 (1, 40, 400 and 1,800 ng mL
-1). Accuracy (percent
of recovery) was evaluated as [mean found concentration/
theoretical concentration] 9 100. Precision was given by
the percent relative standard deviations (RSD, CV%). The
criteria for acceptability of the data included accuracy
within ±15% deviation from the nominal values and a
precision within 15% RSD except for LLOQ, where it
should not exceed ±20% of CV.
Within-day precision and accuracy were determined by
repeated analysis (n = 5) of the samples at different QC
levels (1, 40, 400 and 1,800 ng mL
-1 of DL76 in serum) on
the same day. Between days precision and accuracy were
determined by repeated analysis on three consecutive days.
The concentration of each sample was determined using the
calibration curve prepared and analyzed on the same day.
Extraction Recovery
Extraction recoveries of DL76 from serum were deter-
mined at low, medium and high concentrations. Recoveries
were calculated by comparing the mean peak areas
obtained for extracted QC samples (1, 40, 400 and
1,800 ng mL
-1) with those of blank extracts reconstituted
in the mobile phase with standards added at appropriate
concentrations which represented the 100% recovery value.
The recovery value of the IS was determined in the same
way at a single concentration of 250 ng mL
-1.
Stability
Freeze and Thaw Stability
QC serum samples at four concentration levels were stored
at the storage temperature (-30 C) for 24 h and thawed
unassisted at room temperature, then the samples were
refrozen for 24 h. After three freeze–thaw cycles samples
were analyzed.
Short-Term Stability
QC serum samples at four concentration levels were kept at
room temperature for a period that exceeded the routine
sample preparation time (about 5 h).
Long-Term Stability
QC serum samples at four concentration levels were kept at
the temperature of -30 C for the period of 2 months and
then analyzed.
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The autosampler stability was conducted by reanalyzing
extracted QC samples kept under autosampler conditions
(10 C) for 24 h.
Samples were considered to be stable where 85–115%
of the initial concentrations were found.
Application of the Assay
Study in Rats—Drug Administration and Sampling
Male Wistar rats, 13–15 weeks of age and weighting
between 200 and 220 g were used for this study. They were
kept under conditions of constant temperature (21–25 C)
and relative humidity of approximately 40–65% with stan-
dard light/dark cycle. Animals were housed instainless steel
cages with suspended wire-mesh ﬂoors (maximum of 5 rats
per cage). Animals were fasted overnight and then weighed.
Rats had free access to water throughout the experimental
period. DL76 compound dissolved in 0.9% sterile isotonic
saline at a dose of 3 mg kg
-1 was administered intrave-
nously. A total number of 30 rats were used in this experi-
ment. Rats were anaesthetized with thiopental at a dose of
70 mg kg
-1 and blood samples were collected by decapi-
tation to microfuge tubes at 5, 10, 30, 60, 120 and 240 min
after dosing (n = 5). Serum was harvested by centrifuging
at 3,000 rpm for 10 min and stored at -30 C until bio-
analysis. Serum samples (100 lL) were spiked with IS and
processed as described above. The study was approved by
the Institutional Animal Care and Ethics Committee of the
Jagiellonian University Medical College, Krakow, Poland.
Non-Compartmental Pharmacokinetic Analysis
Pharmacokinetic parameters were calculated by employing
a non-compartmental approach from the average concen-
tration values, using WinNonlin 3.3 software (Pharsight,
USA). The area under the mean serum concentration versus
time curve extrapolated to inﬁnity (AUC0-inf) was esti-
mated using the log/linear trapezoidal rule. AUMC was
estimated by the calculation of total area under the ﬁrst-
moment curve by combining trapezoid calculation of
AUMC0-t and extrapolated area. The mean residence time
(MRT) was calculated from AUMC0-inf/AUC0-inf. The ter-
minal rate constant (kz) was calculated by log-linear
regression of the drug concentration data in the terminal
phase and the half-life (t1/2) was calculated as 0.693/kz. The
systemic clearance (Cl) was estimated from the adminis-
tered dose divided by AUC0-inf. The volume of distribution
at steady state (Vss) was calculated from Di.v.AUMC/
AUC
2, where Di.v stands for the dose administered intra-
venously in mg kg
-1 of body weight.
Results and Discussion
In the mass spectra of DL76 and IS dominated protonated
molecules [M?H]
? at m/z 276 and m/z 279, respectively.
The product ion spectra of these analytes and proposed
fragmentation paths are presented in Fig. 1. After collision-
induced dissociation, the major fragment ions observed in
each product ion spectrum were at m/z 98 for DL76 and
181 for IS, so the SRM transitions m/z 276?98 and m/z
279?181 were selected for quantitative analysis.
The mobile phase consisting of acetonitrile and water
provided low background noise and fast separation. The
running time of each sample was 20 min. The gradient
used resulted in retention times of 5.45 and 7.67 min for IS
and DL76, respectively, and the remaining time provided
for column equilibration and clean up to avoid carry over
between samples. Presence of formic acid in the mobile
phase improved the sensitivity by promoting ionization of
the analyte. The representative extracted ion chromato-
grams (XIC) of a blank sample and a rat serum sample with
the concentration of DL76 determined at 67.82 ng mL
-1
are shown in Fig. 2a and c, respectively. The number of
theoretical plates is 16,000 and the retention factor 21.55.
The lower limit of quantiﬁcation (LLOQ) for DL76 was
1n gm L
-1, and the limit of detection (LOD) was
0.5 ng mL
-1 with the noise to signal ratio equal 1:3. The
lowest concentration on the calibration curve was chosen
 m/z (amu) 
C H3 N
O
N
N
N O
O
CH3
CH4
+
NO
CH3
C H3
CH4
+
m/z 181 
m/z 126 
(a) 
(b) 
I
n
t
e
n
s
i
t
y
 
(
c
p
s
)
 
I
n
t
e
n
s
i
t
y
 
(
c
p
s
)
 
m/z 98 
Fig. 1 Product ion mass spectra of [M?H
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? ions of PTX (a) and
DL76 (b) and proposed fragmentation paths
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matrices. At LLOQ the precision did not exceed 15%.
The absolute matrix effect for DL76 was 30%, and the
absolute recovery was 60% giving low process efﬁciency
(mean peak area obtained for the analyte added to the
matrix before the extraction to the corresponding area for
the pure solution), but because of high ionization of the
analyte in the ESI source and its good retention on ana-
lytical column the LLOQ was sufﬁcient for the purpose of
conducting pharmacokinetic studies. No relative matrix
effect for studied compound was observed for ﬁve different
serum pools tested, the RSD values did not exceed 5%.
Calibration curve for DL76 compound in serum was
linear over the proposed concentration range
(1–2,000 ng mL
-1). The calibration curve was generated
by weighted (1/x) linear regression analysis.
As seen in Table 1 for each point on the calibration curve
for DL76, the concentration back-calculated from the
equation of the linear regression analysis was always within
thedeviationof3%fromthenominalconcentrationsandthe
relative standard deviations did not exceed ±15%.
Data for within day and between days precision and
accuracy of this method are presented in Table 2. Values of
precision of the method ranged from 1.65 to 15.9% and for
accuracy ranged from 88.74 to 113.43%, generally accep-
ted for bioanalytical methods.
The stability of DL76 in rats serum was investigated
under a variety of storage and process conditions as
described in previous section. Tables 3 and 4 summarize
these results. Compound DL76 showed good stability
during all these tests and there were no stability related
problems during the routine analysis of samples for phar-
macokinetic studies.
Application to Pharmacokinetic Study
The method described above was applied to pharmacokinetic
study,inwhichserumconcentrationsofDL76compoundwere
determined for 4 h after intravenous administration to rats.
The plot of time course for mean serum concentrations
is shown in Fig. 3. A non-compartmental pharmacokinetic
model was used to describe the pharmacokinetics of DL76
following intravenous administration. DL76 was quickly
eliminated with systemic clearance of 13 L h
-1 kg
-1. The
elimination half-life was 84.32 min. The volume of dis-
tribution at the central compartment was 20 L kg
-1 sug-
gesting that there is wide distribution in peripheral tissues.
The detailed pharmacokinetics and tissue distribution of
DL76 will be presented in a separate paper.
Fig. 2 The representative extracted ion chromatograms (XIC) of
blank serum (a), serum sample spiked with the concentration of
1n gm L
-1 of DL76 (b), rat serum sample after i.v. administration
of DL76 in the dose of 3 mg kg
-1, with the concentration of DL76
determined at 67.82 ng mL
-1 (c) and IS (d)
Table 1 Back-calculated
concentrations of calibrators for
DL76
Nominal concentration
of DL76 (ng mL
-1)
Back calculated concentration
(mean ± SD) n = 5
RSD
(%)
Accuracy
(%)
Bias
(%)
1 1.00 ± 0.15 14.81 100 0
10 9.92 ± 1.06 10.66 99.2 -0.8
50 50.58 ± 1.59 3.15 101.16 1.16
100 102.11 ± 7.30 7.15 102.11 2.11
250 250.46 ± 10.82 4.32 100.18 0.18
500 499.36 ± 14.72 2.95 99.87 -0.13
1,000 1,018.52 ± 39.34 3.86 101.85 1.85
2,000 1,992.28 ± 23.40 1.17 99.61 -0.39
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123Conclusion
In this manuscript, we described a sensitive and selective
high performance liquid chromatography–tandem mass
spectrometry method for the analysis of DL76 compound in
rat serum. Validation of the method in selected conditions
shows that the method is selective and precise with linear
response of mass spectrometer. The liquid–liquid extraction
procedures produced clean chromatograms and high and
reproducible recovery was obtained for investigated com-
pound. The method has been successfully employed to
support a number of pilot pharmacokinetic studies.
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Table 2 Within-day and between days accuracy (% of nominal concentration) and precision (%RSD) of DL76 in rat serum
QC i.d QC nominal concentration
(ng mL
-1) n = 5
One day Different days
Precision
(RSD, %)
Mean accuracy
(%)
Precision
(RSD, %)
Mean
accuracy (%)
LLOQ 1 15.09 112.53 12.8 113.43
Low 40 5.95 88.75 9.75 91.27
Medium 400 4.99 95.74 7.81 92.56
High 1,800 1.65 88.74 2.14 89.79
Table 3 Bench top and postpreparative stability of DL 76
QC i.d. QC nominal concentration
(ng mL
-1) n = 5
Stability after 2 h in 20 C
(bench top stability)
Stability after 24 h in 10 C
(post preparative stability)
Mean concentration
found (%)
Accuracy
(%)
CV
(%)
Mean concentration
found (%)
Accuracy
(%)
CV
(%)
LLOQ 1 0.91 91.4 3.0 1.09 85.71 9.52
Low 40 43.62 109.1 6.7 38.57 102.68 6.67
Medium 400 395.52 98.9 11.2 382.4 85.49 3.09
High 1,800 1,800.91 100.1 14.8 1,843.02 106.93 2.43
Table 4 Long term and freeze/thaw stability of DL 76
QC i.d. QC nominal concentration
(ng mL
-1) n = 5
Stability after three freeze/thaw cycles Stability after 2 months in -30 C
(long term stability)
Mean concentration
found (%)
Accuracy
(%)
CV
(%)
Mean concentration
found (%)
Accuracy
(%)
CV
(%)
LLOQ 1 0.98 98.4 5.5 0.88 87.7 13.3
Low 40 42.63 106.6 4.5 44.79 112.0 6.5
Medium 400 374.98 93.7 3.8 401.95 100.5 1.9
High 1,800 1,822.41 101.2 0.8 1,794.94 99.7 1.3
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Fig. 3 Mean plasma concentrations ±SD (n = 5) versus time proﬁle
obtained after a single i.v. dose (3 mg kg
-1) of DL76 compound
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